Using exposure-response and biomarkers to streamline early drug development

Area of Science:

• Pharmacology
• Drug Development
• Biomarker Research

Background:

• Biomarkers (BMs) are crucial for assessing drug effects and disease progression.
• Integrating BMs into pharmacokinetic/pharmacodynamic (PK/PD) modeling streamlines drug development.
• Mechanism-based BMs, linked to drug action and disease pathophysiology, can serve as surrogate markers (SMs).

Purpose of the Study:

• To highlight the strategic use of mechanism-based biomarkers in drug development.
• To demonstrate how BMs facilitate quantitative integration of PK/PD information across species and clinical phases.
• To showcase the application of novel BMs in optimizing dose-finding studies.

Main Methods:

• Utilizing biomarkers based on mechanism of action (MOA) and pathophysiology of disease (POD).
• Establishing exposure-response (E-R) relationships for biomarkers.
• Applying PK/PD modeling and interspecies scaling for dose optimization.
• Using novel biomarkers like P50 and S(pO2) in drug development.

Main Results:

• Mechanism-based BMs enable quantitative integration of PK/PD data, optimizing development time and resources.
• Surrogate markers (SMs) derived from BMs predict clinical outcomes and individualize treatment.
• Early use of novel BMs (P50, S(pO2)) in efaproxiral development showed strong PK/PD correlations and guided dose-finding studies.
• This approach facilitated translation of preclinical data and identified sources of PK/PD variability.

Conclusions:

• Frontloading drug development with mechanism-based BMs is a rational strategy for optimizing PK/PD integration and dose finding.
• Biomarker evaluation through mechanistic, epidemiological, and clinical pharmacology studies is essential for establishing clinically relevant E-R.
• The use of BMs enhances the prediction of clinical efficacy and safety, especially in special populations.